bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-10-1152

Order Name:
Rivaroxaban Level (Xarelto)

 
Useful For:
Measuring rivaroxaban concentration in selected clinical situations (eg, renal insufficiency, assessment of compliance, periprocedural measurement of drug concentration, suspected overdose, advanced age and extremes of body weight)
 
Methodology:
Chromogenic Assay
 
AliasesName:
Xarelto
 
 
 
Test Code:
090-10-1152

Order Name:
Rivaroxaban Level (Xarelto)

 
Collection Specimen Or Container:
Blood/ Sodium citrate tube (Sodium Citrate 3.2% anticoagulant, Blue top) 3 mL, 1 tube
 
Specimen Testing Type:
Citrate plasma, minimum volume 1 mL
Freeze plasma immediately (no longer than 4 hours after collection) at -20oC
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Hemoglobin > 550 mg/dL will be reject.
Lipemia: Triglyceride > 1,151 mg/dL will be reject.
Icterus: Bilirubin > 40 mg/dL will be reject.
Other:
     1.  Clotted specimen will be reject.
     2.  In patients receiving heparin for therapeutic purposes. Blood should not be drawn from a heparin catheter.
 
Specimen Stabillity:
Specimen Type Temperature Time
Plate-poor plasma Room temperature, 18oC to 24oC 1 hour
Refrigerated, 2oC to 8oC 4 hours
 
 
 
Test Code:
090-10-1152

Order Name:
Rivaroxaban Level (Xarelto)

 
Method detail:
Chromogenic Assay
 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 2 hour
 
Performing Location:
Hematology, Laboratory Department, Tel. 13225
 
Specimen Retention Time:
14 days
 
 
 
Test Code:
090-10-1152

Order Name:
Rivaroxaban Level (Xarelto)

 
 
Clinical Information:
Rivaroxaban, an oral anticoagulant that directly inhibits factor Xa, has been approved by the FDA for prophylaxis of thrombosis in atrial fibrillation and surgical patients and treatment of venous thromboembolism (VTE). Unlike warfarin, it does not require routine therapeutic monitoring. However, in selected clinical situations, measurement of drug level would be useful (eg, renal insufficiency, assessment of compliance, periprocedural measurement of drug concentration, suspected overdose, advanced age, and extremes of body weight).
 
Reference Value:
1.  For stroke prevention in nonvalvular atrial fibrillation
     -  Peak concentration: 184-343 ng/mL
     -  Trough concentration: 12-137 ng/mL

2.  For treatment PE/VTE
     -  Peak concentration: 189-419 ng/mL
     -  Trough concentration: 6-87 ng/mL
 
Interpretation:
See Clinical Information for peak and trough drug concentrations observed in clinical trials of Rivaroxaban.
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Liquid Anti-Xa, HemosIL®, Instrumentation Laboratory Company - Bedford, MA 01730-2443 (USA), Instrumentation Laboratory SpA - V.le Monza 338 - 20128 Milano (Italy), 06/2017
  2. https://www.mayocliniclabs.com (Retrieved: 15 Nov 2020)